YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases,…
Avalo Therapeutics, Inc. (NASDAQ:AVTX) is among the best low priced stocks to get rich in 2026. On June 12, BofA started coverage on Avalo Therapeutics, Inc. (NASDAQ:AVTX) with a Buy rating and a price target of $35. According to the firm,…
June S&P 500 E-Mini futures (ESM26) are trending up +0.46% this morning as investors shrugged off an exchange of fire between the U.S. and Iran and awaited the release of the key U.S. jobs report. The U.S. military said on Thursday that Ir…
Biotech stock Avalo Therapeutics skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment. Continue Reading
[Science technology concept. Research and Development. Drug discovery.] metamorworks/iStock via Getty Images * Avalo Therapeutics (AVTX [https://seekingalpha.com/symbol/AVTX]) late Tuesday priced [https://seekingalpha.com/pr/20502304-avalo…
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today an…
(RTTNews) - The biotech sector has always been a space where science, capital, and sentiment intersect in complex ways. From cautious optimism around breakthrough therapies to concerns over valuation and funding cycles, analyst perspective…
For Immediate Release Chicago, IL – April 6, 2026 – Today, Zacks Equity Research discusses Indivior Pharmaceuticals INDV, Catalyst Pharmaceuticals CPRX, Theravance Biopharma TBPH, Relmada Therapeutics RLMD and Avalo Therapeutics AVTX. Indu…
Quick Read Traders and investors return from the long holiday weekend with an eye towards the beginning of the first-quarter earnings season, which starts in earnest next week on April 14th, when the large-cap financials report. Wall Stree…
The drug and biotech sector has been in a recovery mode since mid-2025, after going through a difficult period between 2021 and 2023 backed by strong quarterly results, surging mergers and acquisitions (M&A) activity and pipeline and regul…
Corcept Therapeutics CORT announced that the FDA has approved its selective glucocorticoid receptor antagonist, Lifyorli (relacorilant), in combination with nab-paclitaxel for the treatment of adult patients with platinum-resistant ovarian…
WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced t…
Avalo Therapeutics, Inc. (NASDAQ:AVTX) is one of the top long-term biotechnology stocks to buy. On October 17, Piper Sandler analyst Yasmeen Rahimi reaffirmed her Buy rating on Avalo Therapeutics Inc. (NASDAQ:AVTX), maintaining a price tar…
WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced t…
Biotech investing is often a high-risk, high-reward game, with clinical trial results capable of sending stocks soaring or plummeting. For investors willing to bet on scientific breakthroughs, these three companies with intriguing pipeline…
WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced…
WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced t…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: DA Davidson upgraded Salesforce (CRM) to N…
[Wall Street sign in Lower Manhattan, NYC] georgeclerk Avalo Therapeutics (NASDAQ:AVTX [https://seekingalpha.com/symbol/AVTX]) traded higher in the premarket on Friday after Cantor Fitzgerald initiated its coverage with an Overweight recom…
* Avalo Therapeutics press release [https://seekingalpha.com/pr/20192783-avalo-reports-second-quarter-2025-financial-results-and-recent-business-updates] (NASDAQ:AVTX [https://seekingalpha.com/symbol/AVTX]): Q2 GAAP EPS of -$1.92. * Cash,…
Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026Rita Jain, M.D. appointed to Board of DirectorsCash and short-term investments of approximately $113 million as of June 30, 20…
Investing.com - Stifel maintained its Buy rating and $36.00 price target on Avalo Therapeutics Inc. (NASDAQ:AVTX), representing significant upside from the current price of $6.73, following a virtual non-deal roadshow with the company’s ma…
Avalo Therapeutics, Inc. (NASDAQ:AVTX) is among the best growth stocks to invest in for the next 5 years. On Monday, the management of Avalo Therapeutics, Inc. (NASDAQ:AVTX) revealed its participation in the HCW Annual Inflammation & Immun…
WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the followi…
WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board…
WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will particip…
Mike Heffernan appointed as Chairman of the Board Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Cash on hand of approximately $125 million as of March 31, 2025 expected to…
Avalo Therapeutics WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointmen…
It could be quite beneficial to invest in personalized nutrition stocks for this month in July. Some applications in the personalized nutrition market are now using artificial intelligence and machine learning, or ML, to provide consumers…
Successfully eliminated $35 million debt paving the way for future growth and innovation Divested AVTX-800 series for potential milestone payments of $45 million, fully focusing the pipeline on Avalo’s promising immunology assetsDisclosed…
WAYNE, Pa. and ROCKVILLE, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it has completed the divestiture of its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVT…
WAYNE, Pa. and ROCKVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- In a major achievement, Avalo Therapeutics (Nasdaq: AVTX) proudly announces the payoff of the remainder of its $35 million debt owed to Horizon Technology Finance Corporatio…
WAYNE, Pa. and ROCKVILLE, Md. , Sept. 12, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement (the Purchase Agreement) with AUG Therapeutics, LLC (AUG) to sell its rights,…
WAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the H.C. Wainwright 25th…
Announced AVTX-002 (quisovalimab) did not meet its primary endpoint in its Phase 2 PEAK Trial in non-eosinophilic asthma, however AVTX-002 significantly reduced serum LIGHT levels for study duration indicating strong target engagement Disc…
Avalo Therapeutics Announced AVTX-002 (quisovalimab) did not meet its primary endpoint in its Phase 2 PEAK Trial in non-eosinophilic asthma, however AVTX-002 significantly reduced serum LIGHT levels for study duration indicating strong tar…